BioSpace News Archive

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with the State of Utah for COVID-19 testing.

Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that new real-life data on safety and overall survival on its lead product, SIR-Spheres® Y-90 resin microspheres, was presented for the first time at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Virtual 2020 Summit on September 14.

Experienced industry physician scientist to lead clinical development Co-founder, Dr. Debasish Roychowdhury, to serve as Chief Technology Officer [15-September-2020] LEXINGTON, Mass. , Sept. 15, 2020 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today its appointment of Edwin Rock , MD, PhD to serve as the c

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it is investing more than $140 million to further expand its laboratory plastics consumables production to support significant global demand for COVID-19 testing, as well as development and manufacturing of therapies and vaccines

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Jardiance® (empagliflozin) to prevent hospitalization for heart failure and reduce the risk of mortality in patients, with and without diabetes, who have had an acute myocardial infarction (more commonly known as a heart attack)

BVI has developed a ‘Patient Pack’ in collaboration with ophthalmic surgeons and administrators to reduce the complexity and concerns in bringing patients back

Jazz Pharmaceuticals is proud to support the American Heart Association’s sleep health educational content Research demonstrates that disrupted sleep and sleep disorders are associated with a higher risk of cardiovascular and cardiometabolic diseases, including obesity, diabetes, heart attack, stroke and coronary artery disease [15-September-2020] DUBLIN , Se

Solution Supports 16-bed ICU With Central Station, Bedside Monitors and Networking Capabilities in One Portable Package

Pharmaceutical companies must seek new skills and foster a more agile culture to maintain a competitive edge.

Aerpio Pharmaceuticals, Inc.(“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, as well as other indications in which the Company believes that activation of Tie2 may have therapeutic potential, including acute respiratory distress syndrome (“ARDS”) associated with COVID-19 infections